3-[3-(Dimethylamino)phenyl]-6-nitro-2-(piperazin-1-ylmethyl)quinazolin-4-one | 1613466-02-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-[3-(Dimethylamino)phenyl]-6-nitro-2-(piperazin-1-ylmethyl)quinazolin-4-one
• CAS: 1613466-02-6
• 化学式: C₂₁H₂₄N₆O₃
• 分子量: 408.46
• InChiKey: PIQXYALQCZSYKY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  97
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2-(2-chloroacetamido)-5-nitrobenzoic acid 在 potassium carbonate 、 三氟乙酸 、 potassium iodide 、 三氯氧磷 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 3-[3-(Dimethylamino)phenyl]-6-nitro-2-(piperazin-1-ylmethyl)quinazolin-4-one
  参考文献：
  名称：

  Development of (E)-2-((1,4-Dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-Amidinophenylbenzamides as Potent Inhibitors of Venezuelan Equine Encephalitis Virus

  摘要：

  Venezuelan equine encephalitis virus (VEEV) is an emerging pathogenic alphavirus that can cause significant disease in humans. Given the absence of therapeutic options available and the significance of VEEV as a weaponized agent, an optimization effort was initiated around a quinazolinone screening hit 1 with promising cellular antiviral activity (EC50 = 0.8 mu M), limited cytotoxic liability (CC50 > 50 mu M), and modest in vitro efficacy in reducing viral progeny (63-fold at 5 mu M). Scaffold optimization revealed a novel rearrangement affording amidines, specifically compound 45, which was found to potently inhibit several VEEV strains in the low nanomolar range without cytotoxicity (EC50 = 0.02-0.04 mu M, CC50 > 50 mu M) while limiting in vitro viral replication (EC90 = 0.17 mu M). Brain exposure was observed in mice with 45. Significant protection was observed in VEEV-infected mice at 5 mg kg(-1) day(-1) and viral replication appeared to be inhibited through interference of viral nonstructural proteins.

  DOI：

  10.1021/jm501203v

文献信息

• Development of (<i>E</i>)-2-((1,4-Dimethylpiperazin-2-ylidene)amino)-5-nitro-<i>N</i>-phenylbenzamide, ML336: Novel 2-Amidinophenylbenzamides as Potent Inhibitors of Venezuelan Equine Encephalitis Virus
  作者：Chad E. Schroeder、Tuanli Yao、Julie Sotsky、Robert A. Smith、Sudeshna Roy、Yong-Kyu Chu、Haixun Guo、Nichole A. Tower、James W. Noah、Sara McKellip、Melinda Sosa、Lynn Rasmussen、Layton H. Smith、E. Lucile White、Jeffrey Aubé、Colleen B. Jonsson、Donghoon Chung、Jennifer E. Golden

  DOI：10.1021/jm501203v

  日期：2014.10.23

  Venezuelan equine encephalitis virus (VEEV) is an emerging pathogenic alphavirus that can cause significant disease in humans. Given the absence of therapeutic options available and the significance of VEEV as a weaponized agent, an optimization effort was initiated around a quinazolinone screening hit 1 with promising cellular antiviral activity (EC50 = 0.8 mu M), limited cytotoxic liability (CC50 > 50 mu M), and modest in vitro efficacy in reducing viral progeny (63-fold at 5 mu M). Scaffold optimization revealed a novel rearrangement affording amidines, specifically compound 45, which was found to potently inhibit several VEEV strains in the low nanomolar range without cytotoxicity (EC50 = 0.02-0.04 mu M, CC50 > 50 mu M) while limiting in vitro viral replication (EC90 = 0.17 mu M). Brain exposure was observed in mice with 45. Significant protection was observed in VEEV-infected mice at 5 mg kg(-1) day(-1) and viral replication appeared to be inhibited through interference of viral nonstructural proteins.